BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26079946)

  • 1. Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER).
    Ma S; Yin N; Qi X; Pfister SL; Zhang MJ; Ma R; Chen G
    Oncotarget; 2015 May; 6(15):13320-33. PubMed ID: 26079946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein-tyrosine phosphatase H1 increases breast cancer sensitivity to antiestrogens by dephosphorylating estrogen receptor at Tyr537.
    Suresh PS; Ma S; Migliaccio A; Chen G
    Mol Cancer Ther; 2014 Jan; 13(1):230-8. PubMed ID: 24227889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating
    Yin N; Lepp A; Ji Y; Mortensen M; Hou S; Qi XM; Myers CR; Chen G
    J Biol Chem; 2017 Sep; 292(36):15070-15079. PubMed ID: 28739874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTPH1 immunohistochemical expression and promoter methylation in breast cancer patients from India: A retrospective study.
    Venkatesh T; Shetty A; Chakraborti S; Suresh PS
    J Cell Physiol; 2019 Feb; 234(2):1071-1079. PubMed ID: 30189107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs).
    Sirinian C; Papanastasiou AD; Degn SE; Frantzi T; Aronis C; Chaniotis D; Makatsoris T; Koutras A; Kalofonos HP
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Protein Tyrosine Phosphatase H1 PTPH1 Supports Proliferation of Keratinocytes and is a Target of the Human Papillomavirus Type 8 E6 Oncogene.
    Taute S; Böhnke P; Sprissler J; Buchholz S; Hufbauer M; Akgül B; Steger G
    Cells; 2019 Mar; 8(3):. PubMed ID: 30875834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor.
    Márquez DC; Lee J; Lin T; Pietras RJ
    Endocrine; 2001 Nov; 16(2):73-81. PubMed ID: 11887937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of epidermal growth factor receptor inhibition in breast cancer.
    Bundred NJ; Chan K; Anderson NG
    Endocr Relat Cancer; 2001 Sep; 8(3):183-9. PubMed ID: 11566609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
    J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
    Itoh T; Hatano R; Horimoto Y; Yamada T; Song D; Otsuka H; Shirakawa Y; Mastuoka S; Iwao N; Aune TM; Dang NH; Kaneko Y; Okumura K; Morimoto C; Ohnuma K
    Cell Death Dis; 2021 May; 12(6):520. PubMed ID: 34021125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
    Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
    Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development.
    Normanno N; De Luca A; Maiello MR; Mancino M; D'Antonio A; Macaluso M; Caponigro F; Giordano A
    Front Biosci; 2005 Sep; 10():2611-7. PubMed ID: 15970523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
    Singh S; Shi Q; Bailey ST; Palczewski MJ; Pardee AB; Iglehart JD; Biswas DK
    Mol Cancer Ther; 2007 Jul; 6(7):1973-82. PubMed ID: 17620428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proximal events in signaling by plasma membrane estrogen receptors.
    Razandi M; Pedram A; Park ST; Levin ER
    J Biol Chem; 2003 Jan; 278(4):2701-12. PubMed ID: 12421825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation.
    Li MY; Lai PL; Chou YT; Chi AP; Mi YZ; Khoo KH; Chang GD; Wu CW; Meng TC; Chen GC
    Oncogene; 2015 Jul; 34(29):3791-803. PubMed ID: 25263444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.